Elisabeth Heath discusses the FDA approval of capivasertib for PTEN-deficient metastatic hormone-sensitive prostate cancer, reviewing CAPItello-281 data in de novo patients randomized to capivasertib plus abiraterone versus abiraterone alone, both with ADT. The hazard ratio was approximately 0.8, with the control…
Nov 03, 2026, 19:00 ET SynKIR™-110 demonstrated faster tumor control with approximately 10-fold lower IFNγ and 30-fold lower TNFα and IL-2 production compared to CD28-based single-chain CAR T in preclinical models Preclinical in vivo data showed reduced exhaustion of tumor-infiltrating SynKIR™-110 T cells…
Nov 04, 2026, 19:00 ET Interim clinical data of SynKIR™-310, a CD19-targeted KIR-CAR T therapy, showed no CRS, ICANS, or DLT in the first two dose levels, coupled with robust antitumor activity in patients with relapsed or refractory B-cell non-Hodgkin Lymphoma (B-NHL) Verismo…
KIRYAT GAT, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Biologics Ltd., an OPKO Health company (NASDAQ:OPK), today announced that the first participant has been dosed in a first-in-human Phase 1/2a clinical trial of OPK-8801001, an investigational, long acting human growth hormone receptor…
American Hospital Association A UVA Health scientist has developed an experimental drug that reversed paralysis and vision loss in a laboratory mouse model of multiple sclerosis (MS), offering a potential new therapy for a disease that currently has no cure.
AstraZeneca’s regulatory filings for a TAGRISSO and ORPATHYS combination have been accepted in Europe and Japan for a form of non-small cell lung cancer. The… AstraZeneca (LSE:AZN) said its filings for the TAGRISSO plus ORPATHYS regimen have been accepted…
Lupus Foundation of America Providing Answers, Support and Hope in California UPDATE: Certolizumab Pegol, CIMZIA®, receives FDA Breakthrough Therapy Designation for the Prevention of Adverse Pregnancy Outcomes in Women with Antiphospholipid Syndrome and Lupus Anticoagulant The IMPACT study assessed the…
Researchers have begun testing whether focused ultrasound can ease persistent voice hearing in people with schizophrenia. The early trial will look at whether repeated sessions are safe and whether any relief lasts. Hearing voices that others do not hear is…
Neal Shore presents the ARASEC trial, a US-only phase 2 single-arm trial of darolutamide plus ADT in metastatic hormone-sensitive prostate cancer, using an external propensity-matched control arm derived from the CHAARTED trial rather than a monotherapy ADT arm. Among roughly 160 patients…
Trial design, systematic reviews, medical statistics, and guideline updates.
An article joins this feed when it matches these terms. Each one is also a search of its own.